MLICM
AXDX

Metropolitan Life Insurance Company (MetLife)’s Accelerate Diagnostics AXDX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-855
Closed -$91.1K – 2540
2020
Q3 		$91.1K Hold
855
– – ﹤0.01% 2268
2020
Q2 		$130K Hold
855
– – ﹤0.01% 2094
2020
Q1 		$71.2K Buy
855
+70
+9% +$9.85K ﹤0.01% 2244
2019
Q4 		$133K Sell
785
-88
-10% -$14.5K ﹤0.01% 2164
2019
Q3 		$162K Hold
873
– – ﹤0.01% 2015
2019
Q2 		$200K Hold
873
– – ﹤0.01% 1892
2019
Q1 		$183K Hold
873
– – ﹤0.01% 1951
2018
Q4 		$100K Hold
873
– – ﹤0.01% 2265
2018
Q3 		$200K Hold
873
– – ﹤0.01% 2015
2018
Q2 		$195K Hold
873
– – ﹤0.01% 1960
2018
Q1 		$199K Hold
873
– – ﹤0.01% 1899
2017
Q4 		$229K Sell
873
-806
-48% -$189K ﹤0.01% 1829
2017
Q3 		$377K Hold
1,679
– – ﹤0.01% 1871
2017
Q2 		$459K Buy
1,679
+61
+4% +$16.5K ﹤0.01% 1754
2017
Q1 		$392K Sell
1,618
-109
-6% -$24.9K ﹤0.01% 1823
2016
Q4 		$358K Hold
1,727
– – ﹤0.01% 1961
2016
Q3 		$471K Hold
1,727
– – ﹤0.01% 1741
2016
Q2 		$249K Hold
1,727
– – ﹤0.01% 2178
2016
Q1 		$248K Buy
1,727
+44
+3% +$6.21K ﹤0.01% 2045
2015
Q4 		$362K Hold
1,683
– – ﹤0.01% 1850
2015
Q3 		$272K Hold
1,683
– – ﹤0.01% 2044
2015
Q2 		$434K Sell
1,683
-99
-6% -$23.6K ﹤0.01% 1842
2015
Q1 		$401K Hold
1,782
– – ﹤0.01% 1673
2014
Q4 		$342K Hold
1,782
– – ﹤0.01% 2037
2014
Q3 		$383K Hold
1,782
– – ﹤0.01% 1897
2014
Q2 		$463K Buy
1,782
+803
+82% +$175K ﹤0.01% 1884
2014
Q1 		$213K Buy
+979
New +$145K ﹤0.01% 2421

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s AXDX Position: Q4 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Accelerate Diagnostics (AXDX) in Q4 2020, closing a stake of 855 shares — an estimated $91.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in AXDX in Q1 2014 and held it in 27 quarters. The position peaked at $471K in Q3 2016. 115 funds tracked by Wall St. Rank hold AXDX as of Q4 2020.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Accelerate Diagnostics position as of Q4 2020 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 855 Accelerate Diagnostics shares in Q4 2020, an estimated $91.1K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Accelerate Diagnostics in Q1 2014 and held it in 27 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Accelerate Diagnostics position peaked at $471K in Q3 2016.
  • 115 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2020, filed 16 Feb 2021.